← All Eterna Therapeutics INC filings

Eterna Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ERNA
Eterna Therapeutics INC
10-K: Ernexa Therapeutics Faces Going Concern Doubt Amidst Nasdaq Compliance Challenges
Ernexa Therapeutics Inc. reported significant losses and a going concern warning in its 2025 annual report, despite recent capital raises and progress in its preclinical cell therapy programs.
NASDAQ
ERNA
Eterna Therapeutics INC
10-K: Eterna Therapeutics Reports Annual Results, Cites Going Concern Uncertainty
Eterna Therapeutics' 2024 10-K filing reveals significant losses, a going concern warning, and strategic shifts in their iMSC therapy development.
NASDAQ
ERNA
Eterna Therapeutics INC
10-K/A: Eterna Therapeutics Files Amended 10-K to Correct Accounting Firm Consent Date
Eterna Therapeutics filed an amendment to its annual report to correct a typographical error in the date of the independent accounting firm's consent.
NASDAQ
ERNA
Eterna Therapeutics INC
10-K: Eterna Therapeutics Outlines Stock Option and Incentive Plans in SEC Filing
Eterna Therapeutics details its stock option and incentive plans, including terms for vesting, exercise, and tax implications, in a recent SEC filing.